Can Semaglutide Kill You? What the Evidence Actually Shows

Has semaglutide caused deaths in clinical trials?

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and enrolled over 1,900 adults with obesity. Adverse events were recorded rigorously. Deaths occurred in both the semaglutide and placebo arms, at rates consistent with the background mortality of that population, and none were attributed by investigators to the medicine itself. That finding has held across the wider semaglutide clinical programme. The word "kill" in searches like this one usually reflects understandable worry rather than a specific documented event. The honest answer is that no regulatory body, including the MHRA or the European Medicines Agency, has concluded that semaglutide at licensed doses causes death directly.

What the trials do show is a tolerability profile dominated by gastrointestinal side effects: nausea, vomiting, diarrhoea and constipation are common, particularly when starting or moving up to a higher dose. These are uncomfortable, occasionally distressing, but not life-threatening for most people. They typically ease as the body adjusts.

What are the serious risks that actually need attention?

Serious adverse events are rare but documented, and they matter. Acute pancreatitis is the most significant. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis across GLP-1 medicines as an infrequent but potentially serious risk. The warning sign is severe, persistent pain in the abdomen that may spread through to the back, sometimes with vomiting. If that happens, stop the medicine and get medical help urgently — it does not resolve by waiting.

Gallbladder problems, including gallstones, occur at a higher rate in people losing weight rapidly on any treatment. Serious allergic reactions, though uncommon, are also a recognised risk: facial swelling, difficulty breathing and a rapid rash require emergency care. Severe dehydration from prolonged vomiting or diarrhoea can stress the kidneys, particularly if someone is also taking medicines that affect kidney function. None of these risks are unique to semaglutide, and all were known to regulators before the medicine was licensed. You can review the full list of precautions on the NHS semaglutide medicine page, which is updated regularly.

For people with a personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, semaglutide is contraindicated; a prescriber will ask about this directly. Similarly, anyone who has had pancreatitis before should discuss this honestly during their consultation.

Does taking Wegovy increase the risk of dying from heart disease?

This is where the evidence is actually reassuring. The SELECT trial, which assessed semaglutide 2.4mg in adults with established cardiovascular disease and overweight or obesity, found a meaningful reduction in the risk of major cardiovascular events compared with placebo. That is a different question from whether the medicine can cause acute harm, but it matters for anyone whose weight-related worry is about their heart. The NICE appraisal of semaglutide for weight management (TA875) also considered the cardiovascular safety profile and concluded the benefit-risk balance supports its use in appropriate patients.

Wegovy has since received a separate UK licence for reducing cardiovascular event risk in eligible adults, recognising this evidence. For weight management, a prescriber still assesses individual suitability before any prescription is issued.

Who should not take semaglutide, and what does that mean for safety?

Pregnancy, breastfeeding and trying to conceive are all situations where semaglutide is not recommended; the medicine should be stopped before attempting conception, and effective contraception is advised during treatment. Under-18s are outside the licensed population. People with certain conditions, including severe gastrointestinal disease or a history of the thyroid conditions mentioned above, need to disclose these during any clinical assessment. These exclusions exist precisely to keep the medicine safe: the risk profile in these groups is either unknown or unfavourable.

If you are considering treatment and want to understand whether your health history means you can take semaglutide, our prescribers review every consultation personally. You can find out more about the Wegovy treatment pathway at nume or read about semaglutide more broadly before deciding whether to go further. A brief look at our FAQs also answers a number of the practical questions people ask before they start. When you are ready, checking your eligibility through a free consultation is the straightforward next step.

One more thing worth knowing: fake semaglutide pens circulating online carry a completely different risk profile. The MHRA has seized counterfeit Wegovy and similar products whose actual contents were unknown or dangerous, and questions about whether semaglutide can be made outside licensed manufacturing highlight exactly why sourcing matters so much. Buying through a GPhC-registered pharmacy, using a real prescription from a real prescriber, removes that risk entirely. If you want to know more about a specific licensed option, our page on Dr Reddy's semaglutide and how it fits into treatment may be a useful place to start.